Literature DB >> 19434043

Cardiac complications after smallpox vaccination.

Luis F Mora1, Akbar H Khan, Laurence S Sperling.   

Abstract

In 2002, the US Federal government initiated a campaign to vaccinate military personnel and members of the civilian population against smallpox to counter a possible bioterrorism attack. More than 1,200,000 military personnel and approximately 40,000 civilians have been vaccinated since that time. The incidence of myopericarditis in these vaccinees has clearly exceeded calculated background rates and has prompted discussion about cardiac inflammation and other potential vaccine-associated cardiac complications such as dilated cardiomyopathy (DCM) and myocardial ischemia. Although it seems reasonable to predict that some cases of smallpox-associated myopericarditis will progress to DCM, only small numbers have been documented so far, and a causal relationship is difficult to ascertain. With regard to myocardial ischemia, both historical and current data do not suggest a causal association with the vaccine. We describe a case report of myopericarditis following smallpox immunization and provide a review of all cardiac complications associated with vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434043     DOI: 10.1097/SMJ.0b013e31819fe55b

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

1.  Myocarditis secondary to smallpox vaccination.

Authors:  Kyle Keinath; Tyler Church; Benjamin Kurth; Edward Hulten
Journal:  BMJ Case Rep       Date:  2018-03-22

Review 2.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

3.  A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.

Authors:  Cheryl X Zhang; Christian Sauder; Tahir Malik; Steven A Rubin
Journal:  Biologicals       Date:  2009-11-06       Impact factor: 1.856

Review 4.  Vaccinating against monkeypox in the Democratic Republic of the Congo.

Authors:  Brett W Petersen; Joelle Kabamba; Andrea M McCollum; Robert Shongo Lushima; Emile Okitolonda Wemakoy; Jean-Jacques Muyembe Tamfum; Beatrice Nguete; Christine M Hughes; Benjamin P Monroe; Mary G Reynolds
Journal:  Antiviral Res       Date:  2018-11-14       Impact factor: 5.970

5.  Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population.

Authors:  Eva-Maria Zitzmann-Roth; Frank von Sonnenburg; Stephan de la Motte; Nathaly Arndtz-Wiedemann; Alfred von Krempelhuber; Nadine Uebler; Jens Vollmar; Garth Virgin; Paul Chaplin
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

6.  Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

Authors:  Edgar Turner Overton; Steven J Lawrence; Eva Wagner; Katrin Nopora; Siegfried Rösch; Philip Young; Darja Schmidt; Christian Kreusel; Sonja De Carli; Thomas P Meyer; Heinz Weidenthaler; Nathaly Samy; Paul Chaplin
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.